China’s fast-track clinical trials are in the spotlight after child deaths

TL;DR - Nature reports on scrutiny of China’s fast-track clinical-trial system following child deaths. A new government policy aims to preserve faster medical innovation while strengthening safety protections.

• The deaths have intensified attention on the risks of accelerated clinical trials.
• China’s policy response seeks to balance trial speed and innovation against patient safety.
• The limited excerpt does not specify the policy’s measures, the therapies involved, or investigation findings.